Ballicules.com

Tobramycin

TOBREX

What it isAminoglycoside inhibiting the 30S ribosomal subunit; Gram-negative and pseudomonal infection, inhaled in cystic fibrosis.

Why this oneBetter antipseudomonal activity than gentamicin, and the inhaled route delivers high airway concentrations with little systemic exposure.

What limits itNephrotoxicity and irreversible ototoxicity, so levels and function are monitored. Once-daily dosing exploits the post-antibiotic effect.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Cystic fibrosis, Pseudomonas aeruginosaAdults & peds ≥6 yrFour 28 mg capsules (112 mg) inhaled BID112 mg BID, 28 days on / 28 days off

Renal Undefined (not studied in serum creatinine ≥2 mg/dL or BUN ≥40; monitor renal function)

Hepatic No adjustment needed (tobramycin not metabolized)

Dosage not adjusted by weight; each dose ≥6 hours apart

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Aminoglycosides can cause fetal harm; systemic absorption after inhalation minimal; advise of potential risk

Lactation No data for inhaled form; systemic tobramycin present in human milk; monitor infant for loose/bloody stools and thrush

⚠ BOXED WARNINGS

Cost, est. cash$10–$500/bag or supply

Generic entry1984

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryD

Defining liabilityUsually well tolerated at replacement doses; excessive dosing can cause agent-specific metabolic or organ toxicity.

Mechanism of action: Tobramycin ballicule

Tobramycin ballicule: receptor binding, kinetics and half-life diagram

Open Tobramycin in the interactive console ↗